Health Topics
Normal Function
The MFSD8 gene provides instructions for making a protein whose function is unknown. The MFSD8 protein is embedded in the membrane of cell compartments called lysosomes, which digest and recycle different types of molecules. It is one of a large group of related proteins called the major facilitator superfamily of secondary active transporter proteins. Proteins in this family move certain molecules within a cell or in and out of cells. While it is likely that the MFSD8 protein transports molecules across the lysosomal membrane, the specific molecules it moves have not been identified.
Health Conditions Related to Genetic Changes
CLN7 disease
At least 30 mutations in the MFSD8 gene have been found to cause CLN7 disease. This condition typically starts in early childhood with the loss of previously acquired skills (developmental regression), recurrent seizures (epilepsy), muscle twitches (myoclonus), difficulty coordinating movements (ataxia), speech impairment, and vision loss. Mental functioning and motor skills (such as sitting and walking) decline with age. Individuals with CLN7 disease typically do not survive past their teens.
MFSD8 gene mutations that cause CLN7 disease likely lead to the production of a protein with altered structure or function. One MFSD8 gene mutation is responsible for almost all cases of CLN7 disease in the Roma population of the Czech Republic. This mutation replaces the protein building block (amino acid) threonine with the amino acid lysine at position 294 in the MFSD8 protein (written as T294K). A variety of other mutations cause the condition in other populations.
It is unclear how an altered MFSD8 protein leads to the severe neurological features of CLN7 disease. CLN7 disease is characterized by the accumulation of proteins and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. These accumulations can cause cell damage leading to cell death. Individuals with CLN7 disease have gradual nerve cell loss in certain parts of the brain, which likely leads to the signs and symptoms of this condition.
More About This Health ConditionOther Names for This Gene
- ceroid-lipofuscinosis neuronal protein 7
- CLN7
- major facilitator superfamily domain-containing protein 8
- MFSD8_HUMAN
- MGC33302
Additional Information & Resources
Tests Listed in the Genetic Testing Registry
Scientific Articles on PubMed
Catalog of Genes and Diseases from OMIM
References
- Kousi M, Siintola E, Dvorakova L, Vlaskova H, Turnbull J, Topcu M, Yuksel D, Gokben S, Minassian BA, Elleder M, Mole SE, Lehesjoki AE. Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain. 2009 Mar;132(Pt 3):810-9. doi: 10.1093/brain/awn366. Epub 2009 Feb 5. Citation on PubMed
- Sharifi A, Kousi M, Sagne C, Bellenchi GC, Morel L, Darmon M, Hulkova H, Ruivo R, Debacker C, El Mestikawy S, Elleder M, Lehesjoki AE, Jalanko A, Gasnier B, Kyttala A. Expression and lysosomal targeting of CLN7, a major facilitator superfamily transporter associated with variant late-infantile neuronal ceroid lipofuscinosis. Hum Mol Genet. 2010 Nov 15;19(22):4497-514. doi: 10.1093/hmg/ddq381. Epub 2010 Sep 7. Citation on PubMed or Free article on PubMed Central
- Siintola E, Topcu M, Aula N, Lohi H, Minassian BA, Paterson AD, Liu XQ, Wilson C, Lahtinen U, Anttonen AK, Lehesjoki AE. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am J Hum Genet. 2007 Jul;81(1):136-46. doi: 10.1086/518902. Epub 2007 May 14. Citation on PubMed or Free article on PubMed Central
- Steenhuis P, Froemming J, Reinheckel T, Storch S. Proteolytic cleavage of the disease-related lysosomal membrane glycoprotein CLN7. Biochim Biophys Acta. 2012 Oct;1822(10):1617-28. doi: 10.1016/j.bbadis.2012.05.015. Epub 2012 Jun 2. Citation on PubMed
The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.